



養和醫療
HKSH MEDICAL GROUP

For Immediate Release

HKSH Cancer Centre Promotes Widespread Adoption of Precision Medicine Collaboration with FWD Hong Kong and Roche Diagnostics to Enhance Awareness of Comprehensive Genomic Profiling

(2 July 2025, Hong Kong) HKSH Cancer Centre (HKSH) has always been committed to providing patients with one-stop, comprehensive services for cancer screening, diagnosis, treatment, and rehabilitation, ensuring that every patient receives the highest level of support throughout their cancer-fighting journey. Recently, HKSH has partnered with FWD Hong Kong (FWD) and Roche Diagnostics (Hong Kong) Limited (Roche) to raise public awareness on precision medicine and cancer genomic testing. HKSH's oncology specialists will share the latest development in cancer diagnosis and treatment through FWD MAX lifestyle experience platform (fwdmax.fwd.com.hk), introducing Comprehensive Genomic Profiling (CGP) and other cutting-edge medical technologies. This collaboration aims to help more patients to benefit from precise and personalised treatments, ultimately improving patient outcome and their quality of life.

Cancer treatment is advancing rapidly with precision medicine emerging as a key direction for development. Among these advancements, CGP enables the simultaneous analysis of multiple cancer types by identifying genetic mutations in a patient's tumour, guiding doctors to formulate more precise and personalised treatment plans. This technology helps doctors accurately match patients with targeted therapies and track genomic changes during tumour resistance, recurrence, and metastasis for adjustment of treatment strategies, thereby improving patient outcome.

HKSH Cancer Centre is currently the only private medical institution in Hong Kong offering in-house CGP testing with the entire process from tissue sampling, laboratory testing to data analysis conducted on-site. CGP test enables the detection of mutations in over 300 cancer-related genes in a single assay and the in-house testing in HKSH Cancer Centre simplifies the testing process without the need to send samples to overseas laboratories, shortening turnaround time. HKSH's dedicated pathology team can also provide reports with a clear and in-depth narrative offering specific guidance for doctors to formulate timely and targeted treatment strategies, maximising the potential for personalised and precise cancer care.

Dr Joseph Chan, Chief Medical Officer of HKSH Medical Group and Deputy Medical Superintendent of Hong Kong Sanatorium & Hospital, said, "In addition to a top-notch medical team, HKSH is also equipped with cutting-edge medical technologies, such as the first proton therapy system in the Greater Bay Area and we are also Hong Kong's only private medical institution offering in-house CGP service. We believe that CGP is the key to achieving precise and personalised cancer management. Based on genetic test results and patient conditions, doctors can provide critical analysis at the time of cancer diagnosis, relapse, or metastasis, thus formulating highly effective and personalised treatment plans. Whether patients need to undergo surgery, chemotherapy, proton therapy, stereotactic radiotherapy, targeted therapy, hormonal therapy, cellular therapy, or immunotherapy, our multidisciplinary medical team will provide the most comprehensive and compassionate support throughout the treatment and recovery process."

Mr Ken Lau, Managing Director of Greater China and Hong Kong Chief Executive Officer, FWD, said, "FWD is committed to collaborating with medical institutions to provide the public with more comprehensive and forward-looking health protection and support services, covering prevention, treatment, and recovery. As cancer becomes increasingly prevalent and poses a major health challenge in Hong Kong, we are pleased to partner with Roche Diagnostics and HKSH Cancer Centre to enhance public awareness of CGP, an advanced diagnostic technology. Through FWD MAX, the public will have access to reliable information on cancer treatment technologies and healthcare content, supporting them in navigating cancer risks."

養和醫療集團有限公司
HKSH Medical Group Limited

香港跑馬地山村道2號
2 Village Road, Happy Valley, Hong Kong

電話 Tel : (852) 2835 8800
傳真 Fax : (852) 2835 8008
電郵 Email : medicalgroup@hksh.com



Members of HKSH Medical Group:

Hong Kong Sanatorium & Hospital | HKSH Healthcare | HKSH Eastern Medical Centre | HKSH Cancer Centre

www.hksh.com



養和醫療
HKSH MEDICAL GROUP

Mr Ronald Lo, General Manager of Roche Diagnostics (Hong Kong) Limited, said, “Roche Diagnostics is committed to leveraging innovative medical technology to explore more advanced diagnostic methods for cancer patients. We are honoured to partner with FWD and HKSH Cancer Centre. Through promoting Comprehensive Genomic Profiling, we hope to enhance public understanding of precision medicine in Hong Kong, enabling more patients to receive appropriate treatment and have more choices and better treatment outcomes on their anti-cancer journey.¹”

HKSH and FWD have a well-established partnership in delivering top-tier medical support while Roche has been at the forefront of advancing the development and scientific research in Hong Kong’s in vitro diagnostics sector. This tripartite collaboration has combined clinical expertise, cutting-edge research, and robust medical insurance support to promote CGP and the widespread adoption of precision cancer medicine.

–END–

For media enquiries, please contact

Corporate Affairs Department

Carol KWOK Tel: 2917 5838

Joyce CHAN Tel: 2917 5835

Email: media@cad.hksh.com

About HKSH Medical Group

Officially launched in September 2017, HKSH Medical Group, through its operating members, adopts a multi-faceted, coordinated approach to promote public health and advanced medicine through relentless efforts in clinical excellence, medical training and research as well as public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare, HKSH Eastern Medical Centre and HKSH Cancer Centre, are dedicated to offering top-quality holistic care to patients, upholding the motto ‘Quality in Service, Excellence in Care.’

Established in 1922, Hong Kong Sanatorium & Hospital is one of the key members of HKSH Medical Group and a leading private hospital in Hong Kong. Living up to its motto of ‘Quality in Service, Excellence in Care’, the Hospital is committed to serving the public as well as promoting medical education and research.

For more information about HKSH Medical Group, please visit <http://www.hksh.com>.

¹ For informational use only; this is not a substitute for professional medical advice. Please consult your doctor or qualified healthcare provider for any health concerns.



養和醫療
HKSH MEDICAL GROUP

Photo Caption:

開啟癌症精準醫療新篇章



Dr Joseph Chan, Chief Medical Officer of HKSH Medical Group and Deputy Medical Superintendent of Hong Kong Sanatorium & Hospital (left), Ken Lau, Managing Director of Greater China and Hong Kong Chief Executive Officer, FWD (middle), and Ronald Lo, General Manager of Roche Diagnostics (Hong Kong) Limited (right) came together to raise public awareness of Comprehensive Genomic Profiling (CGP) and precision cancer medicine.

養和醫療集團有限公司
HKSH Medical Group Limited

香港跑馬地山村道2號
2 Village Road, Happy Valley, Hong Kong

電話 Tel : (852) 2835 8800
傳真 Fax : (852) 2835 8008
電郵 Email : medicalgroup@hksh.com



Members of HKSH Medical Group:

Hong Kong Sanatorium & Hospital | HKSH Healthcare | HKSH Eastern Medical Centre | HKSH Cancer Centre

www.hksh.com